Hyloris Entered into an Exclusive License and Distribution Agreement with AFT Pharmaceuticals for Maxigesic IV in 9 EU Countries
Shots:
- Hyloris is eligible to receive a share of any product-related revenues incl. license fees, milestones & royalties
- Maxigesic IV is a novel, dual mode-of-action non-opioid pain treatment delivered through IV infusions while 2023 is the anticipated year for the initial commercial launches
- The P-III trial results showed that compared to ibuprofen IV or paracetamol IV alone, Maxigesic IV was found to be well-tolerated, had a faster onset of action, provided greater pain relief, and provided the potential to reduce the use of opioids. The drug's effectiveness and safety have been proven in additional studies in a larger population over a longer treatment period
Ref: Globenewswire | Image: Hyloris
Related News:- CardioRenal Systems’ RenalGuard Therapy Device Receives the US FDA’s Breakthrough Device Designation for Cardiac Surgery Associated AKI
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
